| HDAC inhibitors tune miRNAs in extracellular vesicles of dystrophic muscle‐resident mesenchymal cells M Sandonà, S Consalvi, L Tucciarone, M De Bardi, M Scimeca, ... EMBO reports 21 (9), e50863, 2020 | 56 | 2020 |
| HDAC inhibitors for muscular dystrophies: progress and prospects M Sandoná, S Consalvi, L Tucciarone, PL Puri, V Saccone Expert Opinion on Orphan Drugs 4 (2), 125-127, 2016 | 13 | 2016 |
| Determinants of epigenetic resistance to HDAC inhibitors in dystrophic fibro‐adipogenic progenitors S Consalvi, L Tucciarone, E Macrì, M De Bardi, M Picozza, I Salvatori, ... EMBO reports 23 (6), e54721, 2022 | 11 | 2022 |
| Advanced methods to study the cross talk between fibro-adipogenic progenitors and muscle stem cells L Tucciarone, U Etxaniz, M Sandoná, S Consalvi, PL Puri, V Saccone Duchenne Muscular Dystrophy: Methods and Protocols, 231-256, 2018 | 9 | 2018 |
| Synthesis of Novel Hyaluronic Acid Sulfonated Hydrogels Using Safe Reactants: A Chemical and Biological Characterization E Sturabotti, S Consalvi, L Tucciarone, E Macrì, V Di Lisio, I Francolini, ... Gels 8 (8), 480, 2022 | 3 | 2022 |
| Partial resistance to HDAC inhibitors in FAPs of dystrophic muscles at late stages of disease is associated to epigenetic and transcriptional features of cellular senescence S Consalvi, L Tucciarone, E Macrì, M De Bardi, M Picozza, I Salvatori, ... BioRxiv, 2021.04. 26.441412, 2021 | 2 | 2021 |
| Pharmacological tuning of microRNAs in FAP-derived Extracellular Vesicles by HDAC inhibitors promotes regeneration and reduces fibrosis in dystrophic muscles M Sandonà, S Consalvi, L Tucciarone, MD Bardi, M Scimeca, D Angelini, ... bioRxiv, 2020.02. 15.947325, 2020 | | 2020 |
| Epigenetic and transcriptomic profiling of fibro adipogenic progenitors during Duchenne muscular dystrophy progression and histone deacetylase inhibitors treatment L Tucciarone | | 2020 |
